TAT and ischemia: In the Tat-PDIA3-treated group, SOD1 activity also significantly increased (1.422-fold) 24 h after ischemia/reperfusion, which was maintained at 72 h after ischemia/reperfusion when SOD1 activity was significantly higher (1.579-fold) than the vehicle-treated group (Figure 5e).